Jun72022UncategorizedCategory: UncategorizedBy Charlotte Maddalena7 June 2022 Author: Charlotte Maddalena Post navigationPreviousPrevious post:ORPHELIA reports positive results of the bioequivalence study of KIMOZO® (oral suspension of temozolomide)NextNext post:ORPHELIA Pharma and Gustave Roussy announce the publication of the scientific work related to the first temozolomide oral suspensionRelated PostsOrphelia Pharma secures European patent covering KIGABEQ®, the first pediatric formulation of vigabatrin18 April 2024Six new projects supported by our Foundation18 March 2024Four houses for the FAOMA call for projects18 March 2024ORPHELIA Pharma announces the publication of two scientific articles on KIZFIZO, the first pediatric drinkable formulation of temozolomide for the treatment of refractory or relapsed neuroblastoma9 January 2024Seven new projects supported by our Foundation8 January 2024Newsletter December 202318 December 2023
Orphelia Pharma secures European patent covering KIGABEQ®, the first pediatric formulation of vigabatrin18 April 2024
ORPHELIA Pharma announces the publication of two scientific articles on KIZFIZO, the first pediatric drinkable formulation of temozolomide for the treatment of refractory or relapsed neuroblastoma9 January 2024